Shattuck Labs, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Shattuck Labs, Inc. (STTK) on October 22, 2021. The filing reports significant changes to the Company's Board of Directors, including a resignation and two new appointments.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Resignation: Josiah Hornblower resigned as a director and Chairman of the Board effective October 22, 2021. The resignation was not the result of any dispute with the Company.
- Chairman Appointment: Independent director George Golumbeski was appointed to replace Mr. Hornblower as Chairman of the Board.
- New Director Appointment: Dr. Carrie Brownstein was appointed as a member of the Board, effective immediately. She will serve as a Class I director until the 2024 Annual Meeting of Stockholders.
- Committee Assignment: Dr. Brownstein was appointed to the Nominating and Corporate Governance Committee.
Management Commentary and Background
Dr. Brownstein brings over 15 years of experience in the pharmaceutical industry, specifically in developing therapeutics for cancer and rare diseases. Her recent roles include Chief Medical Officer at Cellectis S.A. (since April 2020) and previous leadership positions at Regeneron Pharmaceuticals, Celgene Corporation, and Genentech. She holds an M.D. from Tufts University and is board certified in Pediatrics and Pediatric Hematology and Oncology.
Dr. Brownstein will receive compensation in accordance with the Company's non-employee director compensation policy and will enter into a standard indemnification agreement. No family relationships or undisclosed material interests exist between Dr. Brownstein and other directors or officers.
Key Facts for Investor Verification
- Confirm the effective date of Josiah Hornblower's resignation and George Golumbeski's appointment as Chairman.
- Verify Dr. Carrie Brownstein's tenure as a Class I director through the 2024 Annual Meeting.
- Review the Company's Proxy Statement on Schedule 14A (filed April 22, 2021) for details on non-employee director compensation.
- Check the attached press release (Exhibit 99.1) for additional context on the leadership transition.